Search
for

    Sort by

    Research 481–510 of 1000+

    1. Lupus erythematosus, thyroiditis, alopecia areata and vitiligo – A multiple autoimmune syndrome type 3 case presentation Our Dermatology Online · 2017
    2. 1P-230: Synthesis and in vitro characterization of 68 Ga labeled Fe 3 O 4 nanoparticles for drug delivery 한국공업화학회 연구논문 초록집 · 2016
    3. ORLANDO LIVE SURGERY WORKSHOP XIV: ADVANCING THE INDUSTRY OF HAIR RESTORATION APRIL 3-5 2008 ORLANDO Hair transplant forum international · 2008
    4. Application of 2-Chloro-7-Nitrobenzo-2-Oxa-1, 3-Diazol (NBDCL) for Spectrophotometric Determination of Finasteride in Pharmaceutical Formulation International journal of advanced research in chemical sciences · 2016
    5. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial Pediatric Dermatology · 2023 · 48 citations
    6. Hydroxysteroid Dehydrogenase (17β -HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors:Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels Recent Patents on Endocrine, Metabolic & Immune Drug Discovery · 2007 · 20 citations
    7. FUT vs. FUE Graft Survival: A Side-by-Side Study of 3 Patients Undergoing a Routine 2,000+ Graft Hair Transplantation Hair transplant forum international · 2018 · 13 citations
    8. Itraconazole in the treatment of acute and recurrent vulvovaginal candidosis: comparison of a 1‐day and a 3‐day regimen Mycoses · 2005 · 12 citations
    9. Lrig1-expression confers suppressive function to CD4+ cells and is essential for averting autoimmunity via the Smad2/3/Foxp3 axis Nature Communications · 2023 · 11 citations
    10. Activity of 17β-(N-Alkyl/arylformamido) and 17β-[(N-Alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5α-androstan-3-ones as 5α-Reductase Inhibitors in the Hamster Flank Organ and Ear11The research has been supported by Endorecherche that is seeking patent protection for the new compounds. F. Labrie is President of Endorecherche. Journal of Investigative Dermatology · 1998 · 10 citations
    11. [Cushing syndrome during pregnancy. New diagnostic methods used in 3 cases of adrenal cortex carcinoma]. PubMed · 1992 · 10 citations
    12. Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indol-5(2<i>H</i>)-yl)acetic Acid (Setipiprant/ACT-129968) Journal of Medicinal Chemistry · 2015 · 6 citations
    13. Synthesis and in vitro study of 17β-[N-ureylene-N,N′-disubstituted]-4-methyl-4-aza-5α-androstan-3-ones as selective inhibitors of type I 5α-reductase Bioorganic & Medicinal Chemistry · 1997 · 5 citations
    14. Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program SKIN The Journal of Cutaneous Medicine · 2023 · 4 citations
    15. Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment American Journal of Clinical Dermatology · 2025 · 3 citations
    16. 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies Journal of Investigative Dermatology · 2023 · 3 citations
    17. Long‐Term Follow‐Up of Previously Reported Case of Trichomegaly Associated with Alopecia Areata in a 3‐Year‐Old Girl Pediatric Dermatology · 2012 · 3 citations
    18. Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3 Dermatology · 2024 · 2 citations
    19. 723 - Efficacy of ritlecitinib in patients with alopecia areata by extent of hair loss at baseline: post hoc analysis of the phase 3 long-term ALLEGRO-LT study British Journal of Dermatology · 2024 · 1 citations
    20. 76957 Efficacy and Safety of Upadacitinib in Adolescents and Adults with Severe Alopecia Areata: A Subgroup Analysis of the UP-AA Phase 3 Clinical Program Journal of the American Academy of Dermatology · 2026
    21. 77015 Subgroup Analysis of Efficacy of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata From the UP-AA Phase 3 Program Journal of the American Academy of Dermatology · 2026
    22. Assessment of The Long-Term Negative Impact of Bariatric Surgery on Health in Saudi Adults, over 3 Years after Surgery: A Cross-Sectional Study Saudi Journal of Medicine and Public Health · 2025
    23. Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program SKIN The Journal of Cutaneous Medicine · 2025
    24. Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials SKIN The Journal of Cutaneous Medicine · 2024
    25. Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata SKIN The Journal of Cutaneous Medicine · 2024
    26. Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years 2024
    27. 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata Journal of The American Academy of Dermatology · 2023
    28. Referee report. For: Effect of Aloe vera extract in post-burn skin repair in rats [version 3; peer review: 2 approved, 1 not approved] Faculty of 1000 Research Ltd · 2023
    29. Peer Review Report For: Pattern changes of cutaneous dermatoses among Iraqi women preceding and during the COVID-19 pandemic [version 3; peer review: 2 approved] 2022
    30. Supplementary Images & Discussion - Tolerated, Effective, Successful: Low Dose Oral Minoxidil for Treating Alopecia, A 3-Year North American Retrospective Case Series 2020